Oncolytics Biotech (ONCY) Current Deferred Revenue (2017 - 2024)
Oncolytics Biotech's (ONCY) quarterly Current Deferred Revenue came in at $6.7 million in Q4 2024, up 32.01% on a QoQ basis from $5.1 million in Q4 2019.
Oncolytics Biotech (ONCY) Current Deferred Revenue (2017 - 2024) Analysis & Trends
Oncolytics Biotech (ONCY) has 4 years of Current Deferred Revenue data on file, last reported at $6.7 million in Q4 2024.
- On a quarterly basis, Current Deferred Revenue changed N/A year-over-year to $6.7 million in Q4 2024; TTM through Dec 2024 was $6.7 million, a N/A change from a year earlier, with the FY2024 full-year figure at $6.7 million, changed N/A from the prior year.
- Current Deferred Revenue for Q4 2024 stood at $6.7 million, up from $5.1 million in the prior quarter.
- Over the last five years, Current Deferred Revenue for ONCY reached as high as $6.7 million in Q4 2024 and fell as low as $6.7 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Oncolytics Biotech | 372.40 Mn | 372.40 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 6.73 Mn |
| Dec 31, 2019 | 5.10 Mn |
| Dec 31, 2018 | 5.10 Mn |
| Dec 31, 2017 | 4.87 Mn |